Borrelia antigens

US8303961B2 · kind B2 · utility

Assignee

• Intercell AG · AT

Inventors

• Urban Lundberg · Wien, AT
• Andreas Meinke · Pressbaum, AT
• Eszter Nagy · Wien, AT
• Alexander Von Gabain · Wien, AT
• Birgit Noiges · Wien, AT
• Dieter Gelbmann · Weiden am See, AT
• Albina Poljak · Wien, AT
• Christine Triska · Wien, AT

Key dates

• Filing date: Mar 2, 2012
• Grant date: Nov 6, 2012
• Expiry date: Mar 2, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/53
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.